Recent Updates
Recently added Catalysts
HSCS Positive Sentiment Score: 80/100

HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023

Key Takeaway: Heart Test Laboratories, Inc., operating as HeartSciences, will present at the Planet MicroCap Showcase in Las Vegas from April 25 to 27, 2023. CEO Andrew Simpson is scheduled to deliver a corporate overview on April 26. The company focuses on enhancing ECG screening capabilities through AI technology, aiming to improve cardiac assessments in clinical settings. The MyoVista® wavECG device is its primary product candidate seeking FDA clearance.

Market Sentiment Analysis

POSITIVE FACTORS

  • HeartSciences will showcase its innovative AI-based ECG technology.
  • The presentation will provide opportunities for one-on-one meetings with the CEO.
  • The company's business model is designed for ongoing revenue through proprietary electrodes.

Full Press Release Details

Southlake, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today announces that CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.
The conference is being held on April 25 – 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally’s) in Las Vegas, NV.
Presentation Date:            April 26, 2023
Time:                                 11:00am Pacific Time
Webcast Link:                    https://www.webcaster4.com/Webcast/Page/2963/47983
Mr. Simpson will be available for one-on-one meetings at the conference venue. To request a meeting and to register for the conference, click here: https://planetmicrocapshowcase.com/signup
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed. For more information, please visit: https://www.heartsciences.com.
Twitter: @HeartSciences
For Investor and Media Inquiries, please contact:
Website: www.coreir.com
Phone: +1-737-414-9213 (US)

Tags

Heart Test Laboratories

Frequently Asked Questions

What company will present at the Planet MicroCap Showcase?

Heart Test Laboratories, Inc., operating as HeartSciences, will present.

When is the presentation at the conference?

The presentation is scheduled for April 26, 2023, at 11:00 am PT.

What is the focus of HeartSciences?

HeartSciences focuses on enhancing ECG screening through AI technology.

What is the MyoVista® device?

MyoVista® is an ECG device providing diagnostic info on cardiac dysfunction.

How does the MyoVista® business model work?

It operates on a razor-razorblade model requiring proprietary electrodes for tests.

Last updated: Apr 17, 2023